Chemed (CHE) reported earnings 30 days ago. What's next for the stock?
Chemed Corporation (CHE) receives a Buy rating with a $632/share target, driven by activist pressure for a spin-off to eliminate the conglomerate discount. VITAS has successfully reengineered its patient mix, sharply reducing Medicare Cap penalties and driving 8.8% revenue growth and 18.2% Adjusted EBITDA margin in Q2. Roto-Rooter faces structural margin pressure from rising digital marketing costs, but B2B expansion and operational efficiencies are expected to support future growth.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Kevin J. McNamara CEO | XDUS Exchange | US16359R1032 ISIN |
| US Country | 15,811 Employees | 17 Aug 2026 Last Dividend | 12 May 2005 Last Split | 3 May 1973 IPO Date |
Chemed Corporation, incorporated in 1970 and based in Cincinnati, Ohio, is a provider of hospice and palliative care services across the United States. With a comprehensive network that includes physicians, registered nurses, home health aides, social workers, clergy, and volunteers, the company is dedicated to delivering compassionate care to patients in need. Beyond healthcare, Chemed Corporation diversifies its services through its operation in two distinct segments: VITAS and Roto-Rooter, the latter offering a range of plumbing and related services to both residential and commercial customers.